Skip to main content
SpringerLink
Log in

Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital

  • Original Article
  • Published:
Hormones Aims and scope Submit manuscript

Abstract

Purpose

Diabetic ketoacidosis (DKA) is a rare and life-threatening complication in patients with diabetes. Sodium–glucose co-transporter-2 inhibitors (SGLT2i) have rarely been associated with ketoacidosis. The aim of this retrospective study was to investigate DKA episodes occurring after SGLT2i treatment and to compare them to DKA episodes due to other causes.

Methods

The medical records of the years 2018–2020 related to clinical and biochemical characteristics and to treatment of six patients with DKA due to SGLT2i were reviewed. They were compared to those of 12 patients with DKA due to other causes.

Results

On admission, the most common symptom was abdominal pain. Glucose levels (median, min–max) were lower in patients with SGLT2i-induced DKA compared to those with DKA due to other causes (229 (150–481) vs. 458.5 (332–695) mg/dl, p = 0.007), whereas no statistical difference was observed in HbA1c and in the severity of DKA (pH, HCO3, CO2, and anion gap). The duration of insulin infusion (41 (33–124) vs. 21.50 (11–32) h, p < 0.001) and the time required until DKA resolution (39 (31–120) vs. 19 (9–28) h, p < 0.001) were higher in patients with SGLT2i-induced DKA than those with DKA due to other causes. In addition, there were increased fluid requirements (14 (8–22.75) vs. 5.5 (2–24) L, p = 0.013) and longer hospitalization time (11 (6–22) vs. 5.5 (2–14) days, p = 0.024) in patients with SGLT2i-induced DKA. No statistically significant differences were observed in total intravenous insulin and potassium administration until DKA resolution.

Conclusions

Patients with SGLT2i-induced DKA had lower serum glucose levels on admission and required increased fluid administration and longer time to recover from acidosis compared to patients with DKA from other causes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Benoit SR, Zhang Y, Geiss LS, Gregg EW, Albright A (2018) Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality - United States, 2000-2014. MMWR Morb Mortal Wkly Rep 67:362–365. https://doi.org/10.15585/mmwr.mm6712a3

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN (2009) Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32:1335–1343. https://doi.org/10.2337/dc09-9032

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Garber AJ, Handelsman Y, Grunberger G et al (2020) Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2020 executive summary. Endocr Pract 26:107–139. https://doi.org/10.4158/CS-2019-0472

    Article  PubMed  Google Scholar 

  4. Fattah H, Vallon V (2018) The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus. Drugs 78:717–726. https://doi.org/10.1007/s40265-018-0901-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2212. https://doi.org/10.1056/NEJMoa1504720

    Article  CAS  PubMed  Google Scholar 

  6. Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334. https://doi.org/10.1056/NEJMoa1515920

    Article  CAS  PubMed  Google Scholar 

  7. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925

    Article  CAS  PubMed  Google Scholar 

  8. Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357. https://doi.org/10.1056/NEJMoa1812389

    Article  CAS  PubMed  Google Scholar 

  9. Taylor SI, Blau JE, Rother KI (2015) SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 100:2849–2852. https://doi.org/10.1210/jc.2015-1884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Erondu N, Desai M, Ways K, Meininger G (2015) Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 38:1680–1686. https://doi.org/10.2337/dc15-1251

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Henry RR, Thakkar P, Tong C, Polidori D, Alba M (2015) Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type I diabetes. Diabetes Care 38:2258–2265. https://doi.org/10.2337/dc15-1730

    Article  CAS  PubMed  Google Scholar 

  12. Hamblin PS, Wong R, Ekinci EI et al (2019) SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab 104:3077–3087. https://doi.org/10.1210/jc.2019-00139

    Article  PubMed  Google Scholar 

  13. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB (2015) Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter2 inhibition. Diabetes Care 38:1687–1693. https://doi.org/10.2337/dc15-0843

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Meyer EJ, Gabb G, Jesudason D (2018) SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications. Diabetes Care 41:e47–e49. https://doi.org/10.2337/dc17-1721

    Article  CAS  PubMed  Google Scholar 

  15. Ueda P, Svanström H, Melbye M et al (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365. https://doi.org/10.1136/bmj.k4365

    Article  PubMed  PubMed Central  Google Scholar 

  16. Patakfalvi L, Brazeau AS, Dasgupta K (2018) Physician experiences with sodium-glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects. Prim Health Care Res Dev 23:1–6. https://doi.org/10.1017/S1463423618000476

    Article  Google Scholar 

  17. Blau JE, Tella SH, Taylor SI, Rother KI (2017) Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev 33(8). https://doi.org/10.1002/dmrr.2924

  18. Hayami T, Kato Y, Kamiya H et al (2015) Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig 6:587–590. https://doi.org/10.1111/jdi.12330

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hine J, Paterson H, Abrol E et al (2015) SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol 3:503–504. https://doi.org/10.1016/S2213-8587(15)00204-1

    Article  CAS  PubMed  Google Scholar 

  20. Roach P, Skierczynski P (2016) Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes after treatment with empagliflozin. Diabetes Care 39:e3. https://doi.org/10.2337/dc15-1797

    Article  PubMed  Google Scholar 

  21. Lucero P, Chapela S (2018) Euglycemic diabetic ketoacidosis in the ICU: 3 case reports and review of literature. Case Rep Crit Care 1747850. https://doi.org/10.1155/2018/1747850

  22. Iqbal I, Hamid M, Khan MAA, Kainat A, Tariq S (2019) Dapagliflozin-induced late-onset euglycemic diabetic ketoacidosis. Cureus. 11:e6089. https://doi.org/10.7759/cureus.6089

    Article  PubMed  PubMed Central  Google Scholar 

  23. Diaz-Ramos A, Eilbert W, Marquez D (2019) Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature. Int J Emerg Med 12:27. https://doi.org/10.1186/s12245-019-0240-0

    Article  PubMed  PubMed Central  Google Scholar 

  24. McLachlan G, Keith C, Frauman A (2019) Diabetic ketoacidosis with sodium-glucose cotransporter type 2 inhibitors: a case series. Med J Aust 211:237–237.e1. https://doi.org/10.5694/mja2.50302

    Article  PubMed  Google Scholar 

  25. Dorcely B, Nitis J, Schwartzbard A et al (2020) A case report: euglycemic diabetic ketoacidosis presenting as chest pain in a patient on a low carbohydrate diet. Curr Diabetes Rev. https://doi.org/10.2174/1573399816666200316112709

  26. Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R (2016) SGLT2 inhibitors and the diabetic kidney. Diabetes Care 39(Suppl 2):S165–S171. https://doi.org/10.2337/dcS15-3006

    Article  CAS  PubMed  Google Scholar 

  27. Gerich JE (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27:136–142. https://doi.org/10.1111/j.1464-5491.2009.02894.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Campbell JE, Drucker DJ (2015) Islet α cells and glucagon-critical regulators of energy homeostasis. Nat Rev Endocrinol 11:329–338. https://doi.org/10.1038/nrendo.2015.51

    Article  CAS  PubMed  Google Scholar 

  29. Umpierrez G, Freire AX (2002) Abdominal pain in patients with hyperglycemic crises. J Crit Care 17:63–67. https://doi.org/10.1053/jcrc.2002.33030

    Article  PubMed  Google Scholar 

  30. Jeon JY, Kim SK, Kim KS et al (2019) DKA Study Group of Gyeonin Branch of the Korean Diabetes Association Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors. Diabetes Metab 45:453–457. https://doi.org/10.1016/j.diabet.2019.01.001

    Article  CAS  PubMed  Google Scholar 

  31. Goldenberg RM, Berard LD, Cheng AYY et al (2016) SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther 38:2654–2664.e1. https://doi.org/10.1016/j.clinthera.2016.11.002

    Article  CAS  PubMed  Google Scholar 

  32. Handelsman Y, Henry RR, Bloomgarden ZT et al (2016) American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 22:753–762. https://doi.org/10.4158/EP161292.PS

    Article  PubMed  Google Scholar 

  33. Danne T, Garg S, Peters AL et al (2019) International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 42:1147–1154. https://doi.org/10.2337/dc18-2316

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Rafey MF, Butt A, Coffey B et al (2019) Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis. Endocrinol Diabetes Metab Case Rep 19-0087:EDM190087. https://doi.org/10.1530/EDM-19-0087

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Endocrinology and Diabetes Center, Athens General Hospital “G. Gennimatas”, 154 Mesogion Avenue, 115 27, Athens, Greece

    Labrini Papanastasiou, Spyridoula Glycofridi, Christos Gravvanis, Nikitas Skarakis, Irene Papadimitriou, Georgia Kanti, Chara Kapsali & Theodora Kounadi

Authors
  1. Labrini Papanastasiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Spyridoula Glycofridi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christos Gravvanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nikitas Skarakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Irene Papadimitriou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Georgia Kanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chara Kapsali
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Theodora Kounadi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Labrini Papanastasiou.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

The study protocol is approved from the Scientific Committee of the General Hospital of Athens ‘G Gennimatas’, Greece (reference number 15238/30.06.2020), and the reporting of the study conforms to the Guidelines for Good Clinical Practice, the Declaration of Helsinki.

Informed consent

Informed consent for research and scientific reasons is routinely collected from each patient admitted to the Endocrinology Unit.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Papanastasiou, L., Glycofridi, S., Gravvanis, C. et al. Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital. Hormones 20, 369–376 (2021). https://doi.org/10.1007/s42000-020-00256-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42000-020-00256-0

Keywords

Search

Navigation